In September 2025, The Prostate Project, a Guildford-based volunteer-led charity, will launch a £250,000 campaign to raise funds for a prostate cancer research project widely anticipated to be ‘game-changing’.
Work has begun to develop a vaccine to prevent the return of prostate cancer in men who have undergone a radical prostatectomy, the surgical removal of the prostate. Cancer vaccines have become an exciting area of research in recent years, and this new treatment could potentially save the lives of more than 1500 men each year in the UK alone.
The Prostate Project, based at the Stokes Centre for Urology at Royal Surrey County Hospital, has a proven track record of funding research and treatment of prostate cancer, raising more than £11 million since its formation in 1998.
During this time the charity has provided funds for research at the University of Surrey, leading directly to breakthroughs in the diagnosis and treatment of prostate and other urological cancers. The university team is one of the leading groups for immunotherapy research in the UK, and is recognised around the world for its work.
This latest initiative is part of the charity's longstanding and ongoing support for the work of Dr Nicola Annels and Dr Guy Simpson and their team based at the University of Surrey.
A patent has been applied for the vaccine and Dr Simpson has already proven that it works in the similar treatment of bladder cancer. This new research is required to see if the vaccine works as effectively for prostate cancer patients.
Dr Guy Simpson, Research Fellow Oncology at the University of Surrey explains: "The research will focus on a ‘prime-boost’ vaccine strategy. The new cancer-killing virus, known as HSV5-15 developed by our team at the University of Surrey will be used as an immune ‘priming’ vaccine along with a prostate specific mRNA vaccine to ‘boost’ and maintain this immune response against the prostate. mRNA vaccines have already proven to be revolutionary in preventing Covid, and this technology is promising similarly effective results in treating cancer tumours. The vaccine trains the body’s immune system to recognise cancer cells so any that return after surgery can be hunted down and killed, reducing the risk of the disease coming back. Around 5000 radical prostatectomies are performed each year in the UK, but between 20% and 50% of men who have their prostates removed will have their cancer return, resulting in them undergoing further radiotherapy and / or hormone therapy. This treatment is costly, time-consuming and can have unpleasant side effects, and is not always completely successful."
Prostate Project Chairman, Martin Davies, expands on the fundraising initiative: "For over 25 years the Prostate Project has been proud to support a team that is quite rightly recognised by their peers for their work in immunology research, and this latest initiative is perhaps the most important yet. We are looking to raise £250,000, a target that we recognise as ambitious but completely achievable, especially given our past record, and the significance of the potential outcome."
And a final word from Dr Simpson on the timescales for delivery: "This funding will support the initial 18-month research period, but the more money that we raise will have a significant effect on timescales."
The Prostate Project website features a comprehensive FAQ page with answers to many of the questions about the vaccine and details of how to donate.
E: info@prostate-project.org.uk
T: +44 (0)7724 465883
